Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC

被引：0
|
作者：
de Azevedo, Ricardo A.
Turner, Broderick
Jayaprakash, Priyamvada
Bhanu, Krithikaa Rajkumar
Srinivasamani, Anupallavi
Morrow, Brittany
Winkler, Michelle
Hedge, Shweta Mahendra
Liu, Arthur
Slay, Ravaen
Curran, Michael A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5745
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
    Kim, Yunjae
    Kim, Gihyeon
    Kim, Sujeong
    Cho, Beomki
    Kim, Sang-Yeob
    Do, Eun-Ju
    Bae, Dong-Jun
    Kim, Seungil
    Kweon, Mi-Na
    Song, Joon Seon
    Park, Sang Hyoung
    Hwang, Sung Wook
    Kim, Mi-Na
    Kim, Yeongmin
    Min, Kyungchan
    Kim, Sung-Han
    Adams, Mark D.
    Lee, Charles
    Park, Hansoo
    Park, Sook Ryun
    [J]. CELL HOST & MICROBE, 2024, 32 (08)
  • [2] The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma
    Park, Jong Chul
    Durbeck, Julia
    Boudadi, Karim
    Ho, Wen Jin
    Kang, Hyunseok
    [J]. ORAL ONCOLOGY, 2020, 108
  • [3] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [4] Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.
    Park, Sook Ryun
    Kim, Gihyeon
    Kim, Yunjae
    Cho, Beomki
    Kim, Sang-Yeob
    Do, Eun-Ju
    Bae, Dong-Jun
    Kweon, Mi-Na
    Song, Joon Seon
    Park, Hansoo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
    Fu, Jianyang
    McGrath, Nicole A.
    Lee, Jihye
    Wang, Xin
    Brar, Gagandeep
    Xie, Changqing
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (05) : 485 - 492
  • [6] Enhancement of anti-PD-1 antitumor efficacy in syngeneic preclinical models by the angiogenesis inhibitor lucitanib
    Dusek, Rachel L.
    Robillard, Liliane
    Harding, Thomas C.
    Simmons, Andrew D.
    Minh Nguyen
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [7] Targeting CAFs to Improve Anti-PD-1 Checkpoint Immunotherapy
    Tauriello, Daniele V. F.
    [J]. CANCER RESEARCH, 2023, 83 (05) : 655 - 656
  • [8] Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism
    Lan, Xiucai
    Ma, Jiaming
    Huang, Zhipeng
    Xu, Yuzhen
    Hu, Yaomin
    [J]. JOURNAL OF GENE MEDICINE, 2024, 26 (01):
  • [9] The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Kuk, Deborah
    Ott, Patrick A.
    Johnson, Douglas B.
    Tsai, Katy K.
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Sullivan, Ryan J.
    Luke, Jason J.
    Gangadhar, Tara C.
    Salama, April K. S.
    Clark, Varina
    Burias, Clare
    Puzanov, Igor
    Atkins, Michael B.
    Algazi, Alain P.
    Ribas, Antoni
    Wolchok, Jedd D.
    Postow, Michael A.
    [J]. CANCER, 2016, 122 (21) : 3354 - 3362
  • [10] The efficacy and safety of anti-PD-1 therapy in metastatic sarcomas
    Yang, Jilong
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345